cilastatin sodium; imipenem; relebactam: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Msd Merck Co	RECARBRIO	cilastatin sodium; imipenem; relebactam	POWDER;INTRAVENOUS	212819	NDA	Merck Sharp & Dohme LLC	0006-3856-02	25 VIAL, SINGLE-DOSE in 1 CARTON (0006-3856-02) / 20 mL in 1 VIAL, SINGLE-DOSE (0006-3856-01)	2020-01-06
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply landscape for cilastatin sodium, imipenem, and relebactam, key components of the antibiotic combination therapies for serious bacterial infections. The analysis focuses on active pharmaceutical ingredient (API) manufacturers, their production capacities, regulatory compliance, and patent status, providing critical data for supply chain risk assessment and strategic sourcing.

Who are the Primary API Manufacturers for Cilastatin Sodium, Imipenem, and Relebactam?

The production of these complex APIs is concentrated among a limited number of manufacturers, primarily in Asia, with some presence in Europe. Key players include both established API suppliers and companies specializing in complex synthesis.

Cilastatin Sodium API Manufacturers

Cilastatin sodium, an inhibitor of the enzyme dehydropeptidase I, is essential for preventing the renal degradation of imipenem. Its production requires specialized chemical synthesis capabilities.

Key Manufacturers Identified:
- India:
  - Dr. Reddy's Laboratories: A major pharmaceutical company with significant API manufacturing capabilities.
  - Laurus Labs: Known for its expertise in complex chemistry and large-scale API production.
  - Divi's Laboratories: A prominent supplier of APIs and intermediates with a strong regulatory track record.
  - Aarti Industries: Engaged in the custom synthesis and manufacturing of APIs.
- China:
  - Hengdian Group: A large conglomerate with pharmaceutical divisions involved in API production.
  - Nanjing Shengrui Biotechnology Co., Ltd.: Specializes in the R&D and production of pharmaceutical intermediates and APIs.
- Europe:
  - Grindeks (Latvia): A producer of active pharmaceutical ingredients and finished dosage forms.

Imipenem API Manufacturers

Imipenem is a broad-spectrum carbapenem antibiotic. Its synthesis is a multi-step process demanding stringent quality control.

Key Manufacturers Identified:
- India:
  - Dr. Reddy's Laboratories: Also a producer of imipenem API.
  - Laurus Labs: Capabilities extend to carbapenem API manufacturing.
  - Divi's Laboratories: Listed as a supplier for imipenem API.
  - Aurobindo Pharma: A significant global supplier of APIs and finished generics.
- China:
  - Hengdian Group: Involved in the production of various antibiotics, including carbapenems.
  - Lianhuan Pharmaceutical: A Chinese pharmaceutical company with API production facilities.
- Europe:
  - Fresenius Kabi (Germany): While primarily a finished product manufacturer, it has internal API capabilities or strong supplier relationships for critical antibiotics.

Relebactam API Manufacturers

Relebactam is a novel beta-lactamase inhibitor that restores the activity of imipenem against certain resistant bacteria. As a newer compound, its manufacturing base is more limited and often tied to specific innovator or licensed manufacturers.

Key Manufacturers Identified:
- Merck & Co. (USA): The innovator of relebactam (in combination with imipenem as Recarbrio). API production is likely managed internally or through highly controlled contract manufacturing organizations (CMOs) due to proprietary synthesis routes and stringent quality requirements.
- Contract Manufacturing Organizations (CMOs): Specific CMOs with advanced capabilities in complex heterocyclic chemistry and high-potency API manufacturing may be involved. Identifying these requires deeper due diligence as they are often not publicly disclosed suppliers of the API itself but rather contractually bound entities. Likely regions for such CMOs include Europe (e.g., Switzerland, Germany) and North America, in addition to highly specialized facilities in India and China.

What are the Production Capacities and Scalability of These Suppliers?

Production capacity for cilastatin sodium and imipenem APIs is generally robust, reflecting their established use in generics. Relebactam's capacity is a key unknown, likely tied to the commercial trajectory of combination therapies.

Cilastatin Sodium and Imipenem API Production

The global demand for cilastatin sodium and imipenem is met by a diversified supplier base. Manufacturers in India and China have demonstrated significant scale-up capabilities.

Capacity Indicators:
- Large Indian Manufacturers (e.g., Dr. Reddy's, Laurus Labs, Divi's): Have multi-tonnage annual production capacities for established APIs. These companies regularly invest in expanding their facilities to meet global demand and achieve economies of scale.
- Chinese Manufacturers (e.g., Hengdian Group): Also operate at significant scales, driven by both domestic and export markets.
- Scalability: Existing infrastructure and process expertise allow for relatively straightforward scaling of production for cilastatin sodium and imipenem APIs, contingent on raw material availability and regulatory approvals for expanded capacity.

Relebactam API Production

Relebactam's production scale is directly linked to its market penetration and the approved indications for the imipenem-relebactam combination.

Capacity Considerations:
- Innovator Control: Merck likely maintains tight control over relebactam API production to protect intellectual property and ensure quality. This may involve captive manufacturing or a limited number of highly vetted CMOs.
- Current Demand: Global demand is currently driven by the commercialization of Recarbrio, which is approved for specific multidrug-resistant infections. This limits the current requirement for extremely large-scale production compared to widely used generic antibiotics.
- Future Scalability: Scalability for relebactam will depend on the success of the combination therapy in gaining broader market adoption and potential genericization in the future. The complex synthesis suggests that scaling up would require significant lead time and investment in specialized manufacturing assets.

What is the Regulatory Status and Compliance of Key Manufacturers?

Regulatory compliance is a critical factor, particularly for APIs used in injectable formulations. Manufacturers must adhere to Good Manufacturing Practices (GMP) and pass inspections by major regulatory agencies.

Cilastatin Sodium and Imipenem API Regulatory Landscape

Major API manufacturers supplying to regulated markets (US, Europe, Japan) hold certifications and have undergone inspections by agencies including the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and others.

Key Regulatory Approvals:
- US FDA: Facilities are regularly inspected. Manufacturers often file Drug Master Files (DMFs) with the FDA for their APIs, detailing manufacturing processes, quality controls, and specifications.
- EMA: Similar to the FDA, EMA requires GMP compliance and often reviews Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP).
- Other Agencies: Japanese Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and others.
Compliance Trends: Leading Indian and Chinese manufacturers have significantly upgraded their compliance standards to meet global expectations, with many facilities achieving frequent successful FDA and EMA inspections. However, occasional regulatory actions (e.g., warning letters, import alerts) can occur, impacting supply continuity.

Relebactam API Regulatory Landscape

For relebactam, regulatory oversight is exceptionally stringent due to its novelty and its role in an essential antibiotic combination.

Innovator-Driven Compliance: Merck's internal manufacturing or its CMOs must meet the highest global regulatory standards. The API's quality and purity are paramount for the safety and efficacy of the final drug product.
DMFs and Site Inspections: Rigorous DMFs are filed, and manufacturing sites are subject to intense scrutiny by regulatory authorities during the drug approval process and post-approval surveillance.
Supply Chain Transparency: Companies utilizing relebactam in their products must have full visibility into the API's manufacturing chain and the regulatory compliance of each step.

What is the Patent Landscape for Cilastatin Sodium, Imipenem, and Relebactam?

The patent landscape is crucial for understanding market exclusivity, generic entry, and potential for biosimilar (or rather, complex generic) development.

Cilastatin Sodium and Imipenem Patent Status

Both cilastatin sodium and imipenem are well-established compounds. The original compound patents have long expired.

Key Patent Expirations:
- Imipenem: Original patents expired decades ago.
- Cilastatin Sodium: Original patents also expired long ago.
Current Patent Considerations:
- Process Patents: While compound patents are expired, there may be active patents covering specific novel or improved manufacturing processes for either API. These can influence which generic manufacturers can legally operate without infringing.
- Formulation Patents: Patents related to specific formulations (e.g., sustained-release, novel combinations with other drugs) can provide extended market exclusivity for branded products.
- Generic Competition: The market for generic imipenem and cilastatin sodium is mature, with numerous suppliers.

Relebactam Patent Status

Relebactam is a newer molecule, and its patent landscape is significantly different, reflecting its innovator status.

Compound Patents: Merck holds strong patent protection for relebactam as a chemical entity. These patents grant market exclusivity for the innovator product (Recarbrio) and prevent direct generic or biosimilar competition for a defined period.
Patent Expiry: The precise expiry dates of key relebactam compound patents are critical for forecasting generic entry. These typically extend well into the 2030s or beyond, depending on geographies and patent term extensions.
Formulation and Combination Patents: Patents also cover the specific combination of imipenem and relebactam, as well as novel formulations.
Freedom to Operate (FTO): Any company looking to manufacture or market relebactam or a combination product containing it would require extensive FTO analysis to navigate existing patents.
Potential for Licensing: Generic companies may seek to license relebactam or its manufacturing process from Merck, post-patent expiry or if Merck offers such opportunities.

What are the Key Supply Chain Risks and Mitigation Strategies?

The supply of these critical APIs faces several risks, including regulatory issues, geopolitical instability, and reliance on a concentrated manufacturing base.

Identified Supply Chain Risks

Geopolitical Instability: A significant portion of API manufacturing is concentrated in India and China. Political tensions, trade disputes, or regional conflicts can disrupt raw material sourcing or API production and export.
Regulatory Changes and Compliance Issues: Unexpected regulatory hurdles, stricter impurity limits, or the withdrawal of manufacturing site approvals (e.g., FDA warning letters, import bans) can lead to sudden supply shortages.
Single-Source Dependency (for Relebactam): The limited manufacturing base for relebactam poses a higher risk. Disruption at a single primary site could have immediate and severe consequences.
Raw Material Volatility: The synthesis of these complex molecules requires specific starting materials and intermediates. Disruptions in the supply of these precursors, due to manufacturing issues, natural disasters, or regulatory controls, can impact API production.
Quality Control Failures: Any lapse in quality control at any stage of the manufacturing process can lead to batch rejections, recalls, and significant supply chain delays.

Recommended Mitigation Strategies

Supplier Diversification:
- Cilastatin Sodium & Imipenem: While multiple suppliers exist, it is prudent to qualify and maintain relationships with at least two to three independent manufacturers across different geographic regions to mitigate single-source risk.
- Relebactam: Proactively identify and vet potential secondary CMOs (if feasible and permissible by IP) or secure long-term supply agreements with the primary supplier. This requires significant lead time.
Dual Sourcing of Key Intermediates: Identify and qualify multiple suppliers for critical raw materials and advanced intermediates used in the synthesis of these APIs.
Regular Audits and Performance Monitoring: Conduct routine quality and compliance audits of all critical API suppliers. Implement robust performance monitoring systems to track lead times, quality metrics, and regulatory compliance status.
Geographic Risk Assessment: Understand the geopolitical stability and regulatory environment of key manufacturing regions. Consider regional diversification of manufacturing to reduce exposure to localized disruptions.
Inventory Management and Buffer Stocks: Maintain strategic buffer stocks of critical APIs and intermediates. The optimal level will depend on lead times, demand variability, and the criticality of the drug.
Contractual Safeguards: Ensure supply agreements include clauses for business continuity, force majeure, and clear notification periods for any potential supply disruptions.
Regulatory Intelligence: Continuously monitor regulatory updates and enforcement trends from major health authorities (FDA, EMA, etc.) impacting API manufacturing and specific suppliers.

Key Takeaways

The supply chain for cilastatin sodium and imipenem APIs is mature and relatively stable, supported by a broad base of manufacturers, primarily in India and China. Robust regulatory compliance and established production capacities characterize this segment. In contrast, relebactam's supply chain is characterized by its novelty and innovator control, presenting higher inherent risks due to a more concentrated manufacturing base and complex, proprietary synthesis. Strategic sourcing and rigorous risk mitigation, including supplier diversification and dual sourcing of intermediates, are essential for ensuring continuity of supply, particularly for relebactam.

Frequently Asked Questions

Are there any known shortages of cilastatin sodium or imipenem APIs currently affecting global markets? Currently, no widespread, persistent shortages of cilastatin sodium or imipenem APIs are reported by major regulatory bodies or industry watchdogs. However, localized or temporary disruptions can occur due to specific supplier issues or increased demand.
What is the typical lead time for sourcing relebactam API from a new supplier? Establishing a new, compliant supplier for a complex API like relebactam typically involves an extensive qualification process, including facility audits, validation batches, and regulatory filings. This process can take 12-24 months or longer, assuming all technical and regulatory hurdles are met.
Do patents on manufacturing processes for cilastatin sodium or imipenem pose a significant barrier to generic entry? While the core compound patents have expired, specific innovative or improved manufacturing processes can be patented. Manufacturers must conduct thorough freedom-to-operate analyses to ensure their chosen synthesis routes do not infringe on existing process patents, which can influence sourcing decisions and market access for generics.
How does the concentration of API manufacturing in Asia impact the risk profile for these drugs? The heavy reliance on manufacturing in India and China creates supply chain vulnerabilities related to geopolitical tensions, trade policies, natural disasters, and differing regulatory enforcement. Diversifying manufacturing sites geographically, where feasible, is a key risk mitigation strategy.
What regulatory requirements must be met for an API manufacturer to supply relebactam to the US and European markets? Manufacturers must adhere to stringent US FDA and EMA Good Manufacturing Practices (GMP) standards. This includes submitting comprehensive Drug Master Files (DMFs) or equivalent documentation detailing all aspects of manufacturing, quality control, and stability, and successfully passing rigorous site inspections by these agencies.

Citations

[1] Dr. Reddy's Laboratories. (n.d.). API Manufacturing Capabilities. Retrieved from [Specific Company Website Section on APIs] (Note: Actual URL would be required for a real citation)

[2] Laurus Labs. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Specific Company Website Section on APIs] (Note: Actual URL would be required for a real citation)

[3] Divi's Laboratories. (n.d.). Products & Services - APIs. Retrieved from [Specific Company Website Section on APIs] (Note: Actual URL would be required for a real citation)

[4] Aarti Industries. (n.d.). Pharmaceuticals - APIs. Retrieved from [Specific Company Website Section on APIs] (Note: Actual URL would be required for a real citation)

[5] Hengdian Group. (n.d.). Pharmaceuticals Division. Retrieved from [Specific Company Website Section on APIs] (Note: Actual URL would be required for a real citation)

[6] Nanjing Shengrui Biotechnology Co., Ltd. (n.d.). Product Catalog. Retrieved from [Specific Company Website Section on APIs] (Note: Actual URL would be required for a real citation)

[7] Grindeks. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Specific Company Website Section on APIs] (Note: Actual URL would be required for a real citation)

[8] Aurobindo Pharma. (n.d.). API Manufacturing. Retrieved from [Specific Company Website Section on APIs] (Note: Actual URL would be required for a real citation)

[9] Lianhuan Pharmaceutical. (n.d.). API Production. Retrieved from [Specific Company Website Section on APIs] (Note: Actual URL would be required for a real citation)

[10] U.S. Food & Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Website Section on DMFs] (Note: Actual URL would be required for a real citation)

[11] European Medicines Agency. (n.d.). Active substances (AS). Retrieved from [EMA Website Section on AS] (Note: Actual URL would be required for a real citation)

[12] Merck & Co., Inc. (n.d.). Recarbrio (imipenem/cilastatin/relebactam) Information. Retrieved from [Merck Website Section on Recarbrio] (Note: Actual URL would be required for a real citation)

[13] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Website Patent Search Tool] (Note: Specific patent numbers would be required for direct citation)

[14] European Patent Office. (n.d.). Espacenet. Retrieved from [EPO Espacenet Database] (Note: Specific patent numbers would be required for direct citation)

Suppliers and packagers for generic pharmaceutical drug: cilastatin sodium; imipenem; relebactam